Prostate cancer research: The next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting

Miyahira, Andrea K.; Sharp, Adam; Ellis, Leigh; Jones, Jennifer C.; Kaochar, Salma; Larman, H. Benjamin; Quigley, David A.; Ye, Huihui; Simons, Jonathan W.; Soule, Howard R.

doi:10.1002/pros.23934

Cited by 27 publications

(19 citation statements)

References 208 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (PCa) is one of the most frequently diagnosed solid malignancies in men and has become the fifth leading cause of male cancer death worldwide ( 1 , 2 ). Due to the widespread use of prostate-specific antigen (PSA) serum test and the improvement of overall longevity, the incidence of this disease is increasing.…”

Section: Introductionmentioning

confidence: 99%

A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most frequently diagnosed cancers in males worldwide. Approximately 25% of all patients experience biochemical recurrence (BCR) after radical prostatectomy (RP) and BCR indicates increased risk for metastasis and castration resistance. PCa patients with highly glycolytic tumors have a worse prognosis. Thus, this study aimed to explore glycolysis-based predictive biomarkers for BCR. Expression data and clinical information of PCa samples were retrieved from three publicly available datasets. One from The Cancer Genome Atlas (TCGA) dataset was used as the training cohort, and two from the Gene Expression Omnibus (GEO) dataset (GSE54460 and GSE70769) were used as validation cohorts. Using the training cohort, univariate Cox regression survival analysis, robust likelihood-based survival model, and stepwise multiply Cox analysis were sequentially applied to explore predictive glycolysis-related candidates. A five-gene risk score was then constructed based on the Cox coefficient as the following: (−0.8367*GYS2) + (0.3448*STMN1) + (0.3595*PPFIA4) + (−0.1940*KDELR3) + (0.4779*ABCB6). Receiver operating characteristic curve (ROC) analysis was used to identify the optimal cut-off point, and patients were divided into low risk and high risk groups. Kaplan–Meier analysis revealed that high risk group had significantly shorter BCR free survival time as compared with that in low risk group in training and validation cohorts. In conclusion, our data support the glycolysis-based five-gene signature as a novel and robust signature for predicting BCR of PCa patients.

show abstract

Section: Introductionmentioning

confidence: 99%

A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Indeed, after detection of PCa at an early stage, discrimination of aggressive from indolent tumors, improvement of prognostic evaluation in localized and metastatic tumors, as well as evaluation of treatment response and development of resistance, are major clinical challenges. Remarkably, studies indicate that PCa-derived uEVs may mediate disease progression and be used to monitor PCa patients ( Table 2 ) [ 65 ].…”

Section: Uevs As Biomarkers In the Three Urologic Cancers: Mirna Amentioning

confidence: 99%

Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances

Lourenço

Constâncio

Henrique

et al. 2021

Cancers

View full text Add to dashboard Cite

Urologic cancers are a heterogeneous group of tumors, some of which have poor prognosis. This is partly due to the unavailability of specific and sensitive diagnostic techniques and monitoring tests, ideally non- or minimally invasive. Hence, liquid biopsies are promising tools that have been gaining significant attention over the last decade. Among the different classes of biomarkers that can be isolated from biofluids, urinary extracellular vesicles (uEVs) are a promising low-invasive source of biomarkers, with the potential to improve cancer diagnosis and disease management. Different techniques have been developed to isolate and characterize the cargo of these vesicles; however, no consensus has been reached, challenging the comparison among studies. This results in a vast number of studies portraying an extensive list of uEV-derived candidate biomarkers for urologic cancers, with the potential to improve clinical outcome; however, without significant validation. Herein, we review the current published research on miRNA and protein-derived uEV for prostate, bladder and kidney cancers, focusing on different uEV isolation methods, and its implications for biomarker studies.

show abstract

“…The released tumour antigens activate host immune system, which may lead to the enhancement of the abscopal effect—the effect described following radiotherapy in which tumour shrinkage occurs at non-irradiated tumour sites remote from foci of irradiated tumour. The abscopal effect is hypothesized to result from the generation of systemic antitumour response following radiation-induced immunogenic tumour cell death [ 190 ]. The combination of PRLT with ICIs may increase the neoantigen release from the PCa tumour augmenting the immune activation caused by ICIs thereby leading to improved efficacy.…”

Section: Evidence-based Support For Combination Of Icis and Prltmentioning

confidence: 99%

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

Kgatle

Boshomane

Lawal

et al. 2021

IJMS

View full text Add to dashboard Cite

Emerging research demonstrates that co-inhibitory immune checkpoints (ICs) remain the most promising immunotherapy targets in various malignancies. Nonetheless, ICIs have offered insignificant clinical benefits in the treatment of advanced prostate cancer (PCa) especially when they are used as monotherapies. Current existing PCa treatment initially offers an improved clinical outcome and overall survival (OS), however, after a while the treatment becomes resistant leading to aggressive and uncontrolled disease associated with increased mortality and morbidity. Concurrent combination of the ICIs with radionuclides therapy that has rapidly emerged as safe and effective targeted approach for treating PCa patients may shift the paradigm of PCa treatment. Here, we provide an overview of the contextual contribution of old and new emerging inhibitory ICs in PCa, preclinical and clinical studies supporting the use of these ICs in treating PCa patients. Furthermore, we will also describe the potential of using a combinatory approach of ICIs and radionuclides therapy in treating PCa patients to enhance efficacy, durable cancer control and OS. The inhibitory ICs considered in this review are cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1), V-domain immunoglobulin suppressor of T cell activation (VISTA), indoleamine 2,3-dioxygenase (IDO), T cell Immunoglobulin Domain and Mucin Domain 3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), B7 homolog 3 (B7-H3) and B7-H4.

show abstract

Prostate cancer research: The next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting

Cited by 27 publications

References 208 publications

A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma

A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma

Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach

Contact Info

Product

Resources

About